May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Systemic Administration of IL-6 Receptor Antibody Suppresses Choroidal Neovascularization (CNV) in Mice
Author Affiliations & Notes
  • S. Hohki
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • Y. Saishin
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • H. Mashimo
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • H. Haruta
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • H. Sakaguchi
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • M. Tsujikawa
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • N. Ohguro
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • Y. Tano
    Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
  • Footnotes
    Commercial Relationships S. Hohki, None; Y. Saishin, None; H. Mashimo, None; H. Haruta, None; H. Sakaguchi, None; M. Tsujikawa, None; N. Ohguro, None; Y. Tano, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1745. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Hohki, Y. Saishin, H. Mashimo, H. Haruta, H. Sakaguchi, M. Tsujikawa, N. Ohguro, Y. Tano; Systemic Administration of IL-6 Receptor Antibody Suppresses Choroidal Neovascularization (CNV) in Mice. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1745.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: It has previously been demonstrated that IL-6 is up-regulated by inducing CNV in the murine CNV tissues and IL-6-mediated angiogenesis is dependent on Vascular Endothelial Growth Factor (VEGF). Anti-mouse IL-6 receptor (IL-6R) antibody specifically binds to IL-6R and blocks IL-6 binding to IL-6R. This study sought to determine if systemic administration of IL-6R antibody could suppress CNV in the murine model.

Methods:: Adult C57BL/6 mice were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The effect of subcutaneous injections of IL-6R antibody was tested in mice with laser-induced rupture of Bruch’s membrane at 3 locations in each eye. Mice received subcutaneous injections of 2mg of IL-6R antibody, or vehicle twice a week starting immediately after laser. Fourteen days after laser, mice were perfused with fluorescein-labeled dextran and the area of CNV at Bruch’s membrane rupture sites was measured on choroidal flat mounts by image analysis. For expression studies, mice were administrated IL-6R antibody or vehicle after laser. After 24 hours, mice were euthanized and eyes were dissected and homogenized followed by extraction of mRNA. RT-PCR was used to assess the effect of subcutaneous injection of IL-6R antibody on VEGF mRNA levels.

Results:: Compared to vehicle injections, subcutaneous injections of 2 mg of IL-6R antibody twice a week resulted in significant reductions in CNV area of 20%, (p<0.05). VEGF mRNA was decreased compared to vehicle injected mice.

Conclusions:: These data confirm that IL-6R antibody may provide a new agent for treatment of patients with CNV.

Keywords: choroid: neovascularization • neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×